倍择瑞治疗未控制哮喘的KALOS与LOGOS III期试验取得具有临床意义阳性结果

Core Insights - The KALOS and LOGOS trials demonstrate that AstraZeneca's Breztri Aerosphere (budesonide/glycopyrrolate/formoterol) shows significant statistical and clinical improvement in uncontrolled asthma patients compared to standard ICS/LABA therapy and other combinations [1] Group 1: Clinical Trial Results - The trials indicate that Breztri Aerosphere can effectively combine the benefits of ICS, LAMA, and LABA, improving lung function and preventing severe acute asthma attacks regardless of patients' previous acute attack history [1] - The results highlight a critical need for effective treatment options for asthma patients who do not achieve control with ICS/LABA dual therapy [1] Group 2: Expert Commentary - Professor Alberto Papi emphasizes that many of the 262 million asthma patients globally continue to suffer from uncontrolled symptoms despite dual therapy [1] - AstraZeneca's executives express optimism about the potential of Breztri Aerosphere to address the unmet needs of uncontrolled asthma patients and its established foundation in COPD treatment [1] Group 3: Market Implications - The successful outcomes of the KALOS and LOGOS trials represent a significant milestone for AstraZeneca in the asthma treatment sector, with plans to accelerate the introduction of this innovative therapy in China [1] - The trials included a representative Chinese patient population, indicating a strategic focus on expanding treatment options in emerging markets [1]